Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 microg B.I.D. USING AEROCHAMBER PLUS SPACING DEVICE AND BECLOMETHASONE DIPROPIONATE HFA pMDI 200 microg B.I.D. USING THE VOLUMATIC SPACING DEVICE IN CHILDREN WITH MILD ASTHMA DURING A 2-WEEK TREATMENT PERIOD

Trial Profile

A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 microg B.I.D. USING AEROCHAMBER PLUS SPACING DEVICE AND BECLOMETHASONE DIPROPIONATE HFA pMDI 200 microg B.I.D. USING THE VOLUMATIC SPACING DEVICE IN CHILDREN WITH MILD ASTHMA DURING A 2-WEEK TREATMENT PERIOD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 07 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 19 May 2009 Results presented at 105th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top